v3.26.3
Segment Information (Tables)
12 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Reporting
The following table summarized significant segment expenses for the years ended June 30, 2026 and 2025:

Psychedelic Medicine and Drug Therapies Segment
June 30,
2026
June 30,
2025
(in thousands)
Research and development expenses(5,210)(10,747)
General and administration expenses (excluding stock-based payment)(10,018)(10,273)
Stock-based payment(7,559)(2,609)
Financing expense(883)(24,563)